Helius Medical (HSDT) S-1/A 28 Jun 16 2016 FY IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Mar. 31, 2016
Document Type	S1
Amendment Flag	true
Amendment Description	The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
Document Period End Date	Mar. 31, 2016
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	1,610,853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 2,643,937	$ 418,893
Short-term investment	0	378,000
Receivables	399,106	8,833
Prepaid expenses	502,264	410,621
Other current assets	495,415	0
Total current assets	4,040,722	1,216,347
TOTAL ASSETS	4,040,722	1,216,347
Current liabilities
Accounts payable and accrued liabilities	2,181,154	1,197,804
Shares to be issued	150,000	0
Total current liabilities	2,331,154	1,197,804
Derivative liability	1,725,760	1,581,444
TOTAL LIABILITIES	4,056,914	2,779,248
STOCKHOLDERS' DEFICIT
Common stock (Unlimited Class A common shares authorized); (72,193,209 shares issued and outstanding at March 31, 2016 and 63,104,788 shares issued and outstanding at March 31, 2015)	24,347,930	16,358,093
Additional paid-in capital	2,940,539	2,434,552
Shares to be issued	0	39,545
Accumulated other comprehensive loss	(999,398)	(971,640)
Accumulated deficit	(26,305,263)	(19,423,451)
TOTAL STOCKHOLDERS' DEFICIT	(16,192)	(1,562,901)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 4,040,722	$ 1,216,347

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Mar. 31, 2016	Mar. 31, 2015
Common Stock, Shares Authorized
Common Stock, Shares, Issued	72,193,209	63,104,788
Common Stock, Shares, Outstanding	72,193,209	63,104,788

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Expenses
General and administrative	$ 5,671,598	$ 5,308,371
Research and development	3,645,796	4,500,073
Loss from operations	(9,317,394)	(9,808,444)
Other Income (expense)
Interest expense, net	(46,920)	(176,488)
Other income	150,250	20,074
Change in fair value of derivative liability	2,082,703	(739,375)
Foreign exchange gain (loss)	(18,785)	865,916
Gain on extinguishment of debt	268,334	0
Total Other Income (Loss)	2,435,582	(29,873)
Net loss	(6,881,812)	(9,838,317)
Other comprehensive income (loss)
Foreign currency translation adjustments	(27,758)	(971,640)
Comprehensive loss	$ (6,909,570)	$ (10,809,957)
Net loss per share
Basic	$ (0.10)	$ (0.17)
Diluted	$ (0.12)	$ (0.17)
Weighted average shares outstanding
Basic	66,522,564	57,048,406
Diluted	67,026,545	57,048,406

Consolidated Statements of Stoc

Consolidated Statements of Stockholders Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Mar. 31, 2014	$ 8,510,000	$ 807,157		$ (9,585,134)		$ (267,977)
Beginning Balance (Shares) at Mar. 31, 2014	32,070,052
Stock-based compensation on 2,300,000 options granted		50,303				50,303
Shares issued to consultant for option exercise 1	$ 717					717
Shares issued to consultant for option exercise 1 (Shares)	2,300,000
Shares issued to consultant for option exercise 2	$ 290					290
Shares issued to consultant for option exercise 2 (Shares)	930,031
Fair value of options allocated to share capital on exercise of options	$ 857,460	(857,460)
Recapitalization of Helius Medical Technologies, Inc.		162,890				162,890
Recapitalization of Helius Medical Technologies, Inc. (Shares)	10,000,000
Issuance of common stock for private placement	$ 6,437,041	578,961				7,016,002
Issuance of common stock for private placement (Shares)	15,240,000
Share issuance cost	$ 447,515	(67,709)				(379,806)
Beneficial conversion feature		176,488				176,488
Stock-based compensation on 3,370,000 options granted		1,227,724				1,227,724
Conversion of debenture	$ 1,000,100					1,000,100
Conversion of debenture (Shares)	2,564,705
Stock-based compensation on 100,000 options granted 1		74,190				74,190
Stock-based compensation on 100,000 options granted 2		43,229				43,229
Stock-based compensation on 400,000 options granted		135,564				135,564
Stock-based compensation on 100,000 options granted 3		41,987				41,987
Fair value of non-employee vested options reallocated to derivative liability		(74,190)				(74,190)
Private placement proceeds			$ 39,545			39,545
Net loss for the year				(9,838,317)		(9,838,317)
Translation adjustments					$ (971,640)	(971,640)
Ending Balance at Mar. 31, 2015	$ 16,358,093	2,434,552	39,545	(19,423,451)	(971,640)	(1,562,901)
Ending Balance (Shares) at Mar. 31, 2015	63,104,788
Exercise of finders warrants	$ 11,926					11,926
Exercise of finders warrants (Shares)	14,400
Issuance of common stock for private placement	$ 1,825,937					1,825,937
Issuance of common stock for private placement (Shares)	849,273
Fair value of warrants issued in connection with private placement, classified to derivative liability	$ (360,413)					(360,413)
Issuance of common stock for private placement 2	$ 721,243		$ (39,545)			681,698
Issuance of common stock for private placement 2 (Shares)	335,463
Fair value of warrants issued in connection with private placement, classified to derivative liability 2	$ (135,540)					(135,540)
Issuance of common stock for private placement 3	$ 270,375					270,375
Issuance of common stock for private placement 3 (Shares)	125,756
Fair value of warrants issued in connection with private placement, classified to derivative liability 3	$ (36,569)					(36,569)
Stock option exercise	$ 42,500					42,500
Stock option exercise (Shares)	94,640
Fair value of options exercised	$ 34,378	(34,378)
Shares issued as a debt discount	$ 29,045					29,045
Shares issued as a debt discount (Shares)	30,000
Issuance of common stock upon conversion of convertible note	$ 1,731,667					1,731,667
Issuance of common stock upon conversion of convertible note (Shares)	2,083,333
Fair value of warrants issued in connection with initial borrowing under credit facility, classified to derivative liability	$ (206,667)					(206,667)
Issuance of common stock for draw down of remaining credit facility	$ 5,000,000					5,000,000
Issuance of common stock for draw down of remaining credit facility (Shares)	5,555,556
Fair value of warrants issued in connection with draw down of remaining credit facility, classified to derivative liability 2	$ (796,945)					(796,945)
Share issuance cost	(141,100)					(141,100)
Stock-based compensation on 3,370,000 options granted		656,512				656,511
Stock-based compensation on 100,000 options granted 1		33,483				33,483
Stock-based compensation on 100,000 options granted 2		36,140				36,140
Stock-based compensation on 400,000 options granted		197,637				197,637
Stock-based compensation on 50,000 options granted		7,967				7,967
Stock-based compensation on 750,000 options granted		72,792				72,792
Stock-based compensation on 950,000 options granted		211,274				211,274
Stock-based compensation on 100,000 options granted 3		15,445				15,445
Fair value of non-employee vested options reallocated to derivative liability		(690,885)				(690,885)
Net loss for the year				(6,881,812)		(6,881,812)
Translation adjustments					(27,758)	(27,758)
Ending Balance at Mar. 31, 2016	$ 24,347,930	$ 2,940,539		$ (26,305,263)	$ (999,398)	$ (16,192)
Ending Balance (Shares) at Mar. 31, 2016	72,193,209

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (6,881,812)	$ (9,838,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liability	(2,082,703)	739,375
Interest accretion	29,045	176,488
Stock-based compensation	1,231,250	2,340,876
Gain on extinguishment of debt	(268,334)	0
Unrealized foreign exchange loss (gain)	(120,876)	(598,929)
Changes in operating assets and liabilities:
Receivables	(390,273)	(8,945)
Prepaids and other current assets	(91,644)	(110,873)
Accounts payable and accrued liabilities	487,935	979,040
Shares to be issued	150,000	0
Net cash used in operating activities	(7,937,412)	(6,321,285)
Cash flows from investing activities
Proceeds from (purchase of) the sale of short term investment	378,000	(378,000)
Net cash provided by (used in) investing activities	378,000	(378,000)
Cash flows from financing activities
Cash acquired on recapitalization	0	23,904
Proceeds from the issuance of common stock, net	7,636,910	6,637,203
Proceeds from shares to be issued	0	39,545
Exercise of warrants and stock options	54,426	0
Proceeds from issuance of convertible debt	2,000,000	632,076
Proceeds from issuance of promissory note	200,000	0
Repayment of promissory note	(200,000)	0
Proceeds from bridge loan	0	150,000
Net cash provided by financing activities	9,691,336	7,482,728
Effect of foreign exchange rate changes on cash	93,120	(380,518)
Net change in cash and cash equivalents	2,225,044	402,925
Cash and cash equivalents, beginning of the period	418,893	15,968
Cash and cash equivalents, end of the period	2,643,937	418,893
Supplemental cash flow information
Interest paid in cash	1,651	11,144
Income taxes paid in cash	$ 0	$ 0

DESCRIPTION OF BUSINESS AND BAS

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Mar. 31, 2016
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Text Block]	1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Helius Medical Technologies, Inc. (the “Company”) is engaged primarily in the medical technology industry focused on neurological wellness. The Company’s planned principal operations include the development, licensing and acquisition of unique and non-invasive platform technologies to amplify the brain’s ability to heal itself. To date the Company has not generated any revenue. The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. The Company’s head office is located in Newtown, Pennsylvania. The Company is currently listed on the Toronto Stock Exchange (the “TSX”). The Company began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol “HSM”, and subsequently moved to the TSX on April 18, 2016. The Company also began trading on the OTCQB under the ticker symbol “HSDT” on February 10, 2015. On June 13, 2014, the Company completed its acquisition of 100% of the issued and outstanding shares of Neurohabilitation Corporation (“Neuro”), a private company incorporated in Delaware, USA, on January 22, 2013. Prior to the transaction, the Company was a non-operating public shell company. Accordingly, for financial reporting purposes, this transaction was deemed to be a capital transaction in substance and recorded as a reverse recapitalization of Neuro whereby Neuro is deemed to be the continuing, surviving entity for accounting purposes, but through reorganization, has deemed to have adopted the capital structure of the Company. Because the acquisition was considered a reverse recapitalization for accounting purposes, the combined historical financial statements of Neuro became the historical financial statements and from the completion of the acquisition on June 13, 2014, the financial statements have been prepared on a consolidated basis. The assets and liabilities of Neuro have been brought forward at their book value and no goodwill has been recognized in connection with the transaction. The Company had a wholly-owned subsidiary, 0995162 B.C. Ltd, which was dissolved on October 23, 2014. On December 17, 2014, Neuro incorporated a wholly-owned subsidiary, Helius Medical Technologies (Canada), Inc. (“Helius Canada”). The financial information is presented in United States Dollars. Going Concern The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has incurred a net loss of $6,881,812 for the fiscal year ended March 31, 2016 and, as of March 31, 2016, the Company has an accumulated deficit of $26,305,263. The Company has not generated any product revenues and has not achieved profitable operations. Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. While the Company had cash and cash equivalents of $2,643,937 as of March 31, 2016, management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year. The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2016
SIGNIFICANT ACCOUNTING POLICIES [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the fair value pricing model for share-based payment transactions and deferred income tax asset valuation allowances. Financial statements include estimates which, by their nature, are uncertain. Actual outcomes could differ from these estimates. Principles of Consolidation The consolidated financial statements include the historic accounts of Neuro and are consolidated with Helius and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less. Concentrations of Credit Risk The Company is subject to credit risk in respect of its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return. Accounts Receivable Accounts receivable are stated at their net realizable value. At March 31, 2016, the accounts receivable balance consisted primarily of GST and QST refunds related to the Company’s Canadian expenditures. Stock-Based Compensation The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the straight line method. Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date are measured and recognized at that date. The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be measured at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Share purchase options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service condition. The Company uses the Black-Scholes option pricing model to calculate the fair value of share purchase options. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. Changes in these assumptions can materially affect the fair value estimate. Foreign Exchange The functional currency of the Company and Helius Canada is the Canadian dollar (“CAD”) and the functional currency of Neuro is the U.S. dollar (“USD”). The Company’s reporting currency is the U.S. dollar. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiary at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange gain (loss) within the consolidated statements of operations. The foreign exchange adjustment in the books of Neuro relating to inter-company advances from Helius that are denominated in Canadian dollars is recorded in the consolidated statements of operations and comprehensive loss. For the years ended March 31, 2016 and 2015, foreign exchange losses of ($18,785) and gains of $865,916 were recognized in the consolidated statements of operations and comprehensive loss. Income Taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 Income Taxes Research and Development Expenses Research and development (“R&D”) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations and materials and supplies. R&D costs are charged to operations when they are incurred. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views their operations and manages their business in one segment. Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the consolidated balance sheet date. Fair Value Measurements The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and the Ximedica project initiation deposit, and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company had certain Level 3 derivative liabilities required to be recorded at fair value on a recurring basis in accordance with U.S. GAAP as at March 31, 2016 and 2015. Unobservable inputs used in the valuation of these liabilities includes volatility of the underlying share price and the expected term. See Note 7. for the inputs used in the Black Scholes model at March 31, 2016 and the rollforward of the warrant liability and see Note 8. for the inputs used in the Black Scholes model at March 31, 2016 and 2015 for the rollforward of the derivative liability for non-employee options. Fair Value Level 1 Level 2 Level 3 March 31, 2016 Liabilities: Non-employee options 521,179 521,179 Warrants 1,204,581 1,204,581 March 31, 2015 Assets: Short-term investments 378,000 378,000 Liabilities: Non-employee options 1,581,444 1,581,444 Warrants - - There were no transfers between any of the levels during the years ended March 31, 2016 and 2015. Basic and Diluted Income (Loss) per Share Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented. The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period. EPS for convertible debt is calculated under the “if-converted” method. Under the if-converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt. The basic and diluted loss per share for the years ended March 31, 2016 and 2015 were calculated as follows: Year ended Year ended $ $ Net loss, basic (6,881,812 ) (9,838,317 ) Effect of dilutive securities: Change in fair value of derivative liability (1,156,002 ) - Net loss, diluted (8,037,814 ) (9,838,317 ) Denominator 66,522,564 57,048,406 Effective of dilutive securities 503,980 - Diluted weighted average common shares outstanding 67,026,545 57,048,406 Basic net loss per share $ (0.10 ) $ (0.17 ) Diluted net loss per shares $ (0.12 ) $ (0.17 ) The following outstanding securities for the years ended March 31, 2016 and 2015 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive: Year ended Year ended March 31, 2016 March 31, 2015 Options outstanding 5,875,360 4,920,000 Warrants outstanding 12,973,009 8,444,400 Total 18,848,369 13,364,400 Recent Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In April 2015, the FASB issued ASU 2015-03 , Interest- Imputation of Interest (Subtopic 835-30) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties

RECAPITALIZATION

RECAPITALIZATION	12 Months Ended
	Mar. 31, 2016
RECAPITALIZATION [Text Block]	3. RECAPITALIZATION On June 13, 2014, the Company completed a recapitalization transaction where the Company acquired 100% of the issued and outstanding shares of Neuro. In exchange, the Company issued a total of 35,300,083 shares to the shareholders of Neuro which merged with a wholly-owned subsidiary of the Company, HMT Mergersub, for the purpose of the three-corner amalgamation. As a result, the former Neuro shareholders owned the majority of the outstanding shares of the Company upon completion of the transaction. Prior to the recapitalization transaction, the Company did not meet the definition of a business. Thus, the transaction is considered to be a capital transaction of Neuro accompanied by a recapitalization. The ongoing Company has adopted the name Helius Medical Technologies, Inc. These consolidated financial statements present the results of Neuro with the exception of common stock which has been retroactively restated to reflect the Recapitalization. In connection with the Recapitalization, the Company advanced Neuro an unsecured loan in the amount of $150,000 (the “Bridge Loan”). The Bridge Loan was for a term of one year commencing on May 30, 2014, and was payable in a lump sum at the end of the term. The Bridge Loan bears interest at a rate of 8% per annum. The net assets acquired were as follows, Cash and cash equivalents $ 23,904 Receivables 1,644 Bridge loan receivable 150,000 Prepaid expenses 5,970 Accounts payable and accrued liabilities (18,628 ) $ 162,890 The recapitalization transaction reflects a credit to additional paid-in capital of $162,890, the carrying value of the net assets of the Company at the time of the reverse merger. In connection to the completion of the transaction, the Company completed a private placement of 15,240,000 units at CAD $0.50 per unit for a total of $7,016,002 (CAD $7,620,000) (Note 7). Each unit consisted of one common share of the Company and one-half of a share purchase warrant. Each whole share purchase warrant is exercisable at CAD $1.00 for a period of twenty-four months. In respect of this private placement, the Company paid aggregate finders’ fees of $379,806 (CAD $412,200) and issued 824,400 finders’ warrants. Each finder’s warrant is exercisable at CAD $1.00 per share for a period of two years.

CONVERTIBLE DEBENTURE

CONVERTIBLE DEBENTURE	12 Months Ended
	Mar. 31, 2016
CONVERTIBLE DEBENTURE [Text Block]	4. CONVERTIBLE DEBENTURE On February 19, 2014, the Company entered into a securities purchase agreement where the Company agreed to sell and issue a note with annual simple interest at 8% (the “Debenture”). A total of $1,000,100 in principal had been received. The Debenture matured on the earliest of (i) February 28, 2015 or such later date as agreed (ii) the closing of a transaction involving a change in control of the Company or (iii) the date of the closing of the Company’s qualified financing being an aggregate amount of at least $2,000,000 (“qualified financing”). Upon completion of a qualified financing, the Debenture would automatically convert into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing. If a qualified financing did not occur on or before the maturity date, at the option of the Company’s board of directors, the outstanding balance of the debenture would be converted into the Company’s equity securities at a conversion price per share determined using a valuation of $8.5 million and the number of shares outstanding at that date. On June 13, 2014, the Debenture matured on the closing of the Company’s qualified financing and converted into 2,564,705 shares of the Company’s common stock. The conversion option of the Debenture was accounted for as a contingent beneficial conversion feature valued at $176,488 which was recorded as interest expense in the consolidated statements of operations and comprehensive loss on settlement of the contingency. Upon conversion of the Debenture, the Company issued a total of 2,564,705 common shares. In addition, the Company paid the Debenture holders $11,131 with respect to the accrued and unpaid interest outstanding.

PROMISSORY NOTE

PROMISSORY NOTE	12 Months Ended
	Mar. 31, 2016
PROMISSORY NOTE [Text Block]	5. PROMISSORY NOTE On September 8, 2015, the Company received $200,000 in exchange for the issuance of a promissory note (the “Promissory Note”). The Promissory Note was to be repaid six months from the date of issuance with interest accruing at the rate of 6% per annum for the first three months and 10% per annum thereafter. In addition, the lender was entitled to receive 30,000 common shares of the Company on the date of the Promissory Note (the “Bonus Shares”) and an additional 30,000 common shares every three months thereafter as long as the principal of the loan remained outstanding. During the year ended March 31, 2016, the Company issued the lender 30,000 Bonus Shares valued at $29,045 based on their quoted market value to the lender. This amount was recorded as a debt discount of the Promissory Note at issuance and was being amortized using the effective interest method over the term of the Promissory Note. On October 28, 2015, the Company repaid the Promissory Note in its entirety, along with accrued interest of $1,644. The remaining debt discount was immediately recorded as interest expense on the date of repayment.

CONVERTIBLE NOTE

CONVERTIBLE NOTE	12 Months Ended
	Mar. 31, 2016
CONVERTIBLE NOTE [Text Block]	6. CONVERTIBLE NOTE On October 9, 2015, in connection with an Asset Purchase Agreement, under which the Company licensed the use of its intellectual property in the People’s Republic of China, Taiwan, Singapore, Hong Kong, and the Macau Special Administrative Region, the Company entered into a US$7.0 million funding commitment with A&B Company Limited (“A&B”) in the form of a convertible promissory note. The funding commitment consisted of (i) an initial $2.0 million under the Note (“$2.0 million note” and (ii) an additional $5.0 million funding commitment, upon which the Company could draw down at any time or from time to time during the six-month period beginning on the issuance date of the promissory note. The $2.0 million note would accrue interest at a rate equal to 6% per annum, payable in cash on the due date of April 9, 2016. The $2.0 million note was unsecured and was convertible at the option of the holder into units of the Company at $0.96 per unit. Each unit would consist of one share of common stock and one half share purchase warrant exercisable at $1.44 for a period of three years from the date of issuance. Pursuant to the guidance of ASC 815 Derivatives and Hedging On October 9, 2015, the Company received the conversion notice and on November 10 th Derivatives and Hedging As a result of the bifurcation of the embedded conversion option, for accounting purposes, two instruments were considered outstanding and, upon exercise of the contractual conversion option, extinguishment accounting has been applied. Consequently, the shares issued pursuant to the conversion are recorded at their fair value on the date of issuance, determined with reference to their quoted market price on the date of conversion. The resulting difference between the fair value of the shares issued, less the fair value of the related conversion feature and the carrying value of the related debt, is recorded as a gain or loss on the consolidated statement of operations. During the year ended March 31, 2016, the Company recorded a gain on extinguishment of debt of $268,334 in connection with the conversion of the Note. The Company could elect to draw down on the additional $5.0 million funding through the issuance of units of the Company at a price based on the volume weighted average closing price of the Company’s shares of common stock on the date the Company elects to draw down from the commitment (the “Draw Down Price”). Each unit would consist of one shares of common stock of the Company and one half share purchase warrant. The warrant would be exercisable at the price representing a fifty percent ( 50%) premium to the Draw Down Price. On December 29, 2015, the Company drew down the remaining $5.0 million commitment through the issuance of 5,555,556 shares of common stock at a price of $0.90 per share and 2,777,778 warrants exercisable at $1.35 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on January 7, 2016. Pursuant to the guidance of ASC 815 Derivatives and Hedging

COMMON STOCK AND WARRANTS

COMMON STOCK AND WARRANTS	12 Months Ended
	Mar. 31, 2016
COMMON STOCK AND WARRANTS [Text Block]	7. COMMON STOCK AND WARRANTS As of March 31, 2016, the Company’s certificate of incorporation authorized the Company to issue unlimited Class A common shares without par value. Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. No dividends have been declared through March 31, 2016. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company. The Company is subject to a stockholders agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions. Upon completion of the Recapitalization, the Company issued a total of 35,300,083 shares to the shareholders of Neuro (Note 3). In connection with the Recapitalization, the Company also closed a non-brokered private placement (the “Private Placement”) at CAD $0.50 per unit of 15,240,000 units raising $7,016,002 on May 30, 2014 (Note 3). Each unit consists of one common stock of the Company and one half of a warrant of the Company where one full warrant is exercisable for 2 years at CAD $1.00 into one common stock. The fair value of the warrants issued was determined using the Black Scholes option-pricing model and the Company used the relative fair value method to allocate $578,961 of the gross proceeds to Additional Paid-in Capital to account for the warrants issued. On April 30, 2015, the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing. On June 26, 2015, the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing. On July 17, 2015, the Company closed a non-brokered private placement (the “Third Financing”) raising gross proceeds of $270,375 by the issuance of 125,756 units (each a “Third Financing Unit”) at a price of $2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder’s fee of $16,223 in connection with this Third Financing, as well as 7,545 finder’s warrants (the “Third Financing Finder’s Warrants”). Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing. On November 10, 2015, upon conversion of the $2.0 million Note, the Company issued 2,083,333 shares of common stock at a price of $0.96 per share and 1,041,667 warrants exercisable at $1.44 for a period of three years from the date of issuance. See Note 6 “Convertible Note”. On December 29, 2015, the Company drew down the remaining $5.0 million commitment through the issuance of 5,555,556 shares of common stock at a price of $0.90 per share and 2,777,778 warrants exercisable at $1.35 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on January 7, 2016. See Note 6 “Convertible Note”. Pursuant to the guidance of ASC 815 Derivatives and Hedging The warrants having an exercise price denominated in a currency other than the functional currency of the Company that are required to be accounted for as liabilities are summarized as follows for the years ended March 31, 2016 and 2015: Year ended Year ended Fair value of warrants, beginning of the period - - Issuance 1,536,134 - Change in fair value of warrants during the period (331,553) - Fair value of warrants, end of the period 1,204,581 - The warrants are required to be re-valued with the change in fair value of the liability recorded as a gain or loss in the change of fair value of derivative liability, included in other income (expense) in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability. The fair value of warrants as of March 31, 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions: March 31, 2016 Stock price $0.78 Exercise Price $1.62 Expected life 2.65 years Expected volatility 83.86% Risk – free interest rate 0.83% Dividend rate 0.00% The continuity of warrants for the year ended March 31, 2016 is as follows: Number of warrants Weighted Average Exercise Price CAD US CAD US Balance, March 31, 2015 8,444,400 - $ 1.00 - Granted 4,528,609 $ - 1.62 Exercised (14,400 ) - $ 1.00 - Balance, March 31, 2016 8,430,000 4,528,609 $ 1.00 1.62 The warrants outstanding and exercisable at March 31, 2016 are as follows: Number of warrants outstanding Exercise Price Expiry Date 8,430,000 CAD $1.00 May 30, 2016 452,032 US $3.00 April 30, 2018 167,731 US $3.00 June 26, 2018 18,978 US $2.15 June 26, 2020 62,878 US $3.00 July 17, 2018 7,545 US $2.15 July 17, 2020 1,041,667 US $1.44 November 10, 2018 2,777,778 US $1.35 December 29, 2018

SHARE BASED PAYMENTS

SHARE BASED PAYMENTS	12 Months Ended
	Mar. 31, 2016
SHARE BASED PAYMENTS [Text Block]	8. SHARE BASED PAYMENTS On June 18, 2014, the Company’s Board of Directors authorized and approved the adoption of the 2014 Plan (“2014 Plan”), under which an aggregate of 12,108,016 shares of common stock may be issued. Pursuant to the terms of the 2014 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units and deferred stock units. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company. At March 31, 2016, there were 5,432,656 common shares remaining available for grant under the 2014 Plan. The continuity of stock options for the year ended March 31, 2016is as follows: Weighted Average Aggregate Exercise Price Intrinsic Value Number (CAD) (CAD) Balance outstanding at March 31, 2015 4,920,000 $ 1.14 $ 10,120,000 Exercised (94,640 ) $ 0.60 - Granted 1,850,000 $ 0.88 - Balance outstanding at March 31, 2016 6,675,360 $ 1.08 $ 1,580,883 Balance exercisable at March 31, 2016 4,336,864 $ 1.16 $ 1,064,963 The options outstanding and exercisable at March 31, 2016 are as follows: Options outstanding remaining Number of Number of contractual life Exercise Grant date fair options options Expiry date (years) Price (CAD) value (CAD) exercisable 3,520,000 June 18, 2019 3.22 $ 0.60 $ 0.26 2,346,669 155,360 June 20, 2019 3.22 $ 0.60 $ 0.26 155,360 100,000 July 14, 2017 1.29 $ 2.52 $ 1.05 100,000 450,000 December 8, 2019 3.69 $ 2.92 $ 1.65 450,000 100,000 December 8, 2019 3.69 $ 2.92 $ 1.31 66,667 400,000 December 8, 2019 3.69 $ 2.96 $ 1.29 300,000 100,000 March 16, 2020 4.96 $ 3.20 $ 1.42 66,667 50,000 August 15, 2015 4.38 $ 0.98 $ 0.39 16,667 750,000 October 21, 2020 4.56 $ 0.87 $ 0.36 187,500 550,000 October 28, 2020 4.58 $ 0.84 $ 0.44 550,000 400,000 October 28,2020 4.58 $ 0.84 $ 0.36 64,000 100,000 December 31, 2020 4.76 $ 1.24 $ 0.50 33,334 6,675,360 4,336,864 Included in the table above are non-employee awards that are subject to remeasurement each reporting period until vested. As a result, the grant date fair value is not representative of the total expense that will be recorded for these awards. As of March 31, 2016, the unrecognized compensation cost related to non-vested stock options outstanding, was $440,633 to be recognized over a weighted-average remaining vesting period of approximately 0.76 years. The fair value of the employee and director stock options granted during the years ended March 31, 2016 and 2015 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions: March 31, 2016 March 31, 2015 Stock price $0.82 CAD $1.85 CAD Exercise Price $0.87 CAD $2.20 CAD Expected life 3.75 years 3.9 years Expected volatility 67.85% 67.85% Risk – free interest rate 0.63% 1.32% Dividend rate 0.00% 0.00% The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history. The Company recognizes compensation expense for only the portion of awards that are expected to vest. For the years ended March 31, 2016 and 2015, the Company applied an expected forfeiture rate of 0% based on its historical experience. Non-Employee Stock Options In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are re-measured at their respective fair values at each reporting period and accounted for as equity awards until the terms associated with their vesting requirements have been met. The changes in fair of the unvested non-employee awards are reflected in their respective operating expense classification in the Company’s consolidated statements of operations and comprehensive loss. The non-employee stock options that are required to be accounted for as liabilities are summarized as follows for the years ended March 31, 2016 and 2015: Year ended Year ended Fair value of non-employee options, beginning of the period 1,581,444 - Issuance - 767,879 Reallocation of vested non-employee options 690,885 74,190 Change in fair value of non-employee stock options during the period (1,751,150) 739,375 Fair value of non-employee options, end of the period 521,179 1,581,444 The non-employee options that have vested are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability. The fair value of non-employee liability classified awards at March 31, 2016 and 2015 were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: March 31, 2016 March 31, 2015 Stock price $0.97 CAD $3.20 CAD Exercise Price $1.52 CAD $1.90 CAD Expected life 3.23 years 4.24 years Expected volatility 84.62% 67.85% Risk – free interest rate 0.53% 1.31% Dividend rate 0.00% 0.00% Share-based payments are classified in the Company’s statements of operations and comprehensive loss as follows for the years ended March 31, 2016 and 2015: Year ended Year ended Consulting fees 239,064 1,167,281 Research and development 158,396 721,601 Wages and salaries 833,790 451,994 1,231,250 2,340,876

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2016
INCOME TAXES [Text Block]	9. INCOME TAXES The components of net loss for the years ended March 31, 2016 and 2015 are as follows: 2016 2015 $ $ U.S 5,132,611 9,301,988 Non-U.S. 1,749,201 536,329 6,881,812 9,838,317 A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision for the years ended March 31, 2016 and 2015 is as follows: 2016 2015 $ $ Statutory tax rate 34.00% 34.00% Loss before income taxes (6,882,812 ) (9,838,317 ) Expected income tax recovery (2,340,000 ) (3,345,000 ) Increase (decrease) in income tax recovery resulting from: Derivative liability (708,000 ) 251,000 Share based payments 419,000 796,000 Other permanent difference 49,000 12,000 Share issue costs - (140,000 ) Effect of change in statutory rate (147,000 ) (41,000 ) Effect of foreign exchange - 89,000 Effect of over provision in prior year (2,164,000 ) - Foreign income taxed at foreign rate 100,000 14,000 Increase in valuation allowance 4,791,000 2,364,000 Income tax expense - - The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates at March 31, 2016 and 2015 are as follows: 2016 2015 $ $ Deferred income tax assets (liabilities) Operating losses carried forward 4,915,000 2,074,000 Intangible costs - 285,000 Share issuance costs - 99,000 Stock compensation 1,725,000 - Other 609,000 Valuation allowance (7,249,000 ) (2,458,000 ) Net deferred income tax asset - - At March 31, 2016 the Company has accumulated non-capital losses totaling $1,839,442 and in Canada and net operating losses of $12,616,000 in the U.S., which may be available to carry forward and offset future years’ taxable income. The losses expire in various amounts starting in 2033. Under the provisions of the Internal Revenue Code, the net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Section 382 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Uncertain Tax Positions The Company has adopted certain provisions of ASC 740, “Income Taxes”, which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions taken or expected to be taken in income tax returns. The provisions also provide guidance on the de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions. The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the expiration of the respective statutes of limitation. The Company currently has no tax years under examination. At March 31, 2016, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES [Text Block]	10. COMMITMENTS AND CONTINGENCIES (a) On January 22, 2013, the Company entered into a license agreement with ANR for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology. The Company has not made any royalty payments to date under this agreement. (b) On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica where Ximedica will design, develop and produce PoNS™ product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is $499,000 ; phase 2 is $1,065,000 ; Phase 3 and 4 is $1,389,000 and 2nd software development cycle is $586,000, of which $5,191,368 was expensed as research and development since inception to March 31, 2016. Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. The Company recorded a prepaid expense of $274,000 to Ximedica for the upcoming clinical build of the PoNS™ device. As of March 31, 2016, the Company has expensed $120,448 of the $274,000 prepayment. As of March 31, 2016, the Company also recorded a $300,000 project initiation deposit which will be applied once the development-to-supply program has been completed. During the years ended March 31, 2016 and 2015, the Company incurred R&D charges of $1,937,817 and $2,928,289 pursuant to this agreement. (c) On January 27, 2015, the Company received a demand letter containing allegations that it had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainier Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages in excess of $225,000. On December 2, 2015 the Company entered into a settlement agreement with the plaintiffs for an amount of € 57,000 which was subsequently paid on January 12, 2016. The parties have since executed the settlement agreement for the aforementioned amount and the case has been dismissed without prejudice. (d) On January 5, 2015, Wicab Inc. (“Wicab”) filed a complaint against the Company, NHC, its director Mitchell Tyler, and its former director Yuri Danilov, and ANR in the U.S. District Court for the Western District of Wisconsin. The complaint contained various state and common law claims arising from Messrs. Danilov’s and Tyler’s prior employment with Wicab and the Company’s two issued patents for the PoNS™ device. The complaint alleged, among other things, that following their departure from Wicab, Messrs. Danilov and Tyler knowingly filed patent applications for and used ideas and inventions developed at Wicab in violation of various non-competition and confidentiality agreements, and that the Company’s two issued patents are therefore rightfully the property of Wicab. The complaint sought an unspecified amount of monetary damages, an injunction preventing the Company from using the ideas and inventions in the two patents, an order transferring ownership of the patents from the Company to Wicab, and recovery of costs and attorneys’ fees. The complaint was voluntarily dismissed without prejudice on January 14, 2015. On October 12, 2015, the Company received a letter from Wicab alleging that the two issued patents were invalid in view of prior art cited in the letter, including scientific publications and patent applications, and that Paul Bach-y-Rita, Wicab’s founder, should have been named as an inventor on these two issued patents. Wicab indicated in the letter that it may file reexamination or inter partes review proceedings with the U.S. Patent Office to attempt to invalidate the claims in the two issued patents. Wicab also stated that it would consider an unspecified “business solution” to resolve this matter. On December 10, 2015, representatives of each of the Company and Wicab met to discuss the parameters of a potential settlement. There can be no guarantee that a settlement will be reached. In the event that a settlement with Wicab is not reached, Wicab may file reexamination or inter partes review proceedings with the U.S. Patent Office to challenge the validity of the two issued patents. If the Company receives an adverse decision from the U.S. Patent Office in connection with these proceedings, some or all of the claims in the two patents may be invalidated or otherwise impaired, which could prevent the Company from bringing an infringement suit against a future competitor for making use of the PoNS™ technology for neurorehabilitation, and could have a material adverse effect on the Company’s business, operating results and financial condition. Wicab may also take other actions against the Company, its assets, intellectual property rights, officers, directors, employees, agents or other persons or entities which may also have a material effect on the Company’s business, operating results and financial condition. The Company believes that the possibility of an economic outlay is remote. (e) Under the Company’s Asset Purchase Agreement with A&B, if the Company fails to obtain FDA clearance for commercialization of or otherwise fail to ensure that the PoNS™ device is available for purchase by the U.S. Government by December 31, 2017, the Company is subject to a US$2,000,000 contract penalty payable to A&B. (f) In November 2014, the Company signed a development and distribution agreement with the Altair company in Russia to apply for registration and distribute the PoNS™ device in the territories of the former Soviet Union. However, there is no assurance that such commercialization will occur.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2016
RELATED PARTY TRANSACTIONS [Text Block]	11. RELATED PARTY TRANSACTIONS During the years ended March 31, 2016 and 2015, the Company paid $64,210 and $47,100 in consulting fees to directors of the Company. This expense was included in research and development expense. At March 31, 2016, the Company owed $3,450 to a director for consulting services (March 31, 2015: 24,418). During the years ended March 31, 2016 and 2015, a benefit of $195,709 and an expense of $1,040,854 was included in research & development expense as the fair value of stock-based compensation attributed to the options granted to two directors and a consultant for consulting services rendered with respect to the design and development of the PoNS™ device.

SOLE-SOURCE COST-SHARING AGREEM

SOLE-SOURCE COST-SHARING AGREEMENT	12 Months Ended
	Mar. 31, 2016
SOLE-SOURCE COST-SHARING AGREEMENT [Text Block]	12. SOLE-SOURCE COST-SHARING AGREEMENT During the fiscal year ended March 31, 2016, the Company entered into a sole source cost sharing contract executed with the USAMRMC. Under the terms of the contract, the USAMRMC will reimburse the Company up to a maximum of $2,996,244 representing approximately 62% of the Company’s estimated costs for the registrational trial (“the trial”) investigating the safety and effectiveness of the portable neuromodulation stimulator for mild to moderate traumatic brain injury. The trial expires on December 31, 2016 however the Company is working with the USAMRMC to extend the contract into 2017 based on the current trial forecast timelines.. As of March 31, 2016, the Company has received a total of $1,458,374 in respect of expenses reimbursed. All reimbursement amounts received are credited directly to the accounts in which the original expense is recorded, including research and development, wages and salaries, and legal expenses. Under the terms of the agreement, the USAMRMC may terminate their obligation at any time with 30 days written notice.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Mar. 31, 2016
SUPPLEMENTAL CASH FLOW INFORMATION [Text Block]	13. SUPPLEMENTAL CASH FLOW INFORMATION Investing and financing activities that do not have a direct impact on current cash flows are excluded from the consolidated statements of cash flows. During the year ended March 31, 2016, the Company had the following non-cash financing transactions: i) Fair value of warrants issued in conjunction with private placements in April, June and July 2015 was $532,522. ii) Fair value of warrants issued in conjunction with A&B credit facility (including upon conversion of $2.0 million convertible note and draw down of $5.0 million) was $1,003,612. iii) The Company issued 30,000 shares of common stock having a fair value of $29,045 based on the quoted market price as a bonus in connection with the issuance of a promissory note; iv) A gain on extinguishment of debt of $268,334 based on the difference between the fair value of the shares issued to settle the A&B credit facility and the fair value of the related conversion feature and the carrying value of the related debt. During the year ended March 31, 2015: i) the Company issued 2,564,705 common shares valued at $1,000,100 based on the carrying value of the convertible debenture upon its conversion; ii) the Company recorded a beneficial conversion feature of $176,488 in respect of a qualifying transaction recorded in connection with the convertible debenture; iii) the Company recorded a credit to additional paid-in capital of $162,890 representing the carrying values of the net assets acquired in a reverse merger recapitalization transaction.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2016
SUBSEQUENT EVENTS [Text Block]	14. SUBSEQUENT EVENTS On April 18, 2016, the Company closed its short form prospectus offering in Canada and a concurrent U.S. private placement (the "Offering") of units (the "Units") with gross proceeds to the Company of CAD $9,215,000 through the issuance of Units at a price of CAD $1.00 per Unit. Each Unit consists of one Class A common share in the capital of the Company (a “Common Share”) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one additional Common Share at an exercise price of CAD $1.50 on or before April 18, 2019. Mackie Research Capital Corporation (the "Agent") acted as agent and sole bookrunner in connection with the Offering. The Company paid the Agent a cash commission of CAD $436,050 and has granted to the Agent compensation options exercisable to purchase 436,050 Units at an exercise price of CAD $1.00 per Unit for a period of 24 months from the closing of the Offering. As at March 31, 2016, the Company had received $150,000 in respect of the Offering; these funds were reflected as a current liability on Company's consolidated balance sheet as the issuance of the Units in connection with these proceeds was contingent on the Company achieving a minimum financing threshold. Subsequent to March 31, 2016, the Company issued the Units in connection with these proceeds. In addition, the Company has recorded other current assets of $495,415 which represent legal fees pertaining to the Offering invoiced to the Company prior to March 31, 2016. The amount will be recorded as a share issuance cost upon closing of the Offering. On May 2, 2016, the Company closed the sale of the additional units issued pursuant to the exercise of the over-allotment option (“Over-Allotment Option”) granted to the Agent in connection with the Offering. The Offering was made pursuant to a short form prospectus filed with the securities regulatory authorities in each of the provinces of Canada, except Québec. Pursuant to the exercise of the Over-Allotment Option, the Company issued an additional 1,090,125 Units (the "Over-Allotment Units") at a price of CAD $1.00 per Over-Allotment Unit for additional gross proceeds to the Company of CAD $1,090,125, bringing the total aggregate gross proceeds to the Company under the Offering to CAD $10,305,125. Each Over-Allotment Unit consists of one Class A common share in the capital of the Company (an “Over-Allotment Common Share”) and one half of one Common Share purchase warrant (each whole warrant, an “Over-Allotment Warrant”). Each Over-Allotment Warrant entitles the holder thereof to acquire one additional Over-Allotment Common Share at an exercise price of CAD $1.50 on or before April 18, 2019. In connection with the closing of the Over-Allotment Option, the Company paid the Agent a cash commission of CAD $65,408 and granted to the Agent compensation options exercisable to purchase 65,407 Over-Allotment Units at an exercise price of CAD $1.00 per Over-Allotment Unit for a period of 24 months from the closing of the Offering. On June 6 th

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2016
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the fair value pricing model for share-based payment transactions and deferred income tax asset valuation allowances. Financial statements include estimates which, by their nature, are uncertain. Actual outcomes could differ from these estimates.
Principles of Consolidation [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the historic accounts of Neuro and are consolidated with Helius and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less.
Concentrations of Credit Risk [Policy Text Block]	Concentrations of Credit Risk The Company is subject to credit risk in respect of its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are stated at their net realizable value. At March 31, 2016, the accounts receivable balance consisted primarily of GST and QST refunds related to the Company’s Canadian expenditures.
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the straight line method. Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date are measured and recognized at that date.
Foreign Exchange [Policy Text Block]	Foreign Exchange The functional currency of the Company and Helius Canada is the Canadian dollar (“CAD”) and the functional currency of Neuro is the U.S. dollar (“USD”). The Company’s reporting currency is the U.S. dollar. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiary at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange gain (loss) within the consolidated statements of operations. The foreign exchange adjustment in the books of Neuro relating to inter-company advances from Helius that are denominated in Canadian dollars is recorded in the consolidated statements of operations and comprehensive loss. For the years ended March 31, 2016 and 2015, foreign exchange losses of ($18,785) and gains of $865,916 were recognized in the consolidated statements of operations and comprehensive loss.
Income Taxes [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 Income Taxes
Research and Development Expenses [Policy Text Block]	Research and Development Expenses Research and development (“R&D”) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations and materials and supplies. R&D costs are charged to operations when they are incurred.
Segment Information [Policy Text Block]	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views their operations and manages their business in one segment.
Derivative Liabilities [Policy Text Block]	Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the consolidated balance sheet date.
Fair Value Measurements [Policy Text Block]	Fair Value Measurements The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and the Ximedica project initiation deposit, and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company had certain Level 3 derivative liabilities required to be recorded at fair value on a recurring basis in accordance with U.S. GAAP as at March 31, 2016 and 2015. Unobservable inputs used in the valuation of these liabilities includes volatility of the underlying share price and the expected term. See Note 7. for the inputs used in the Black Scholes model at March 31, 2016 and the rollforward of the warrant liability and see Note 8. for the inputs used in the Black Scholes model at March 31, 2016 and 2015 for the rollforward of the derivative liability for non-employee options.
Basic and Diluted Income (Loss) per Share [Policy Text Block]	Basic and Diluted Income (Loss) per Share Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented. The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period. EPS for convertible debt is calculated under the “if-converted” method. Under the if-converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt. The basic and diluted loss per share for the years ended March 31, 2016 and 2015 were calculated as follows: Year ended Year ended $ $ Net loss, basic (6,881,812 ) (9,838,317 ) Effect of dilutive securities: Change in fair value of derivative liability (1,156,002 ) - Net loss, diluted (8,037,814 ) (9,838,317 ) Denominator 66,522,564 57,048,406 Effective of dilutive securities 503,980 - Diluted weighted average common shares outstanding 67,026,545 57,048,406 Basic net loss per share $ (0.10 ) $ (0.17 ) Diluted net loss per shares $ (0.12 ) $ (0.17 ) The following outstanding securities for the years ended March 31, 2016 and 2015 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive: Year ended Year ended March 31, 2016 March 31, 2015 Options outstanding 5,875,360 4,920,000 Warrants outstanding 12,973,009 8,444,400 Total 18,848,369 13,364,400
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In April 2015, the FASB issued ASU 2015-03 , Interest- Imputation of Interest (Subtopic 835-30) In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

SIGNIFICANT ACCOUNTING POLICI22

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2016
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Level 1 Level 2 Level 3 March 31, 2016 Liabilities: Non-employee options 521,179 521,179 Warrants 1,204,581 1,204,581 March 31, 2015 Assets: Short-term investments 378,000 378,000 Liabilities: Non-employee options 1,581,444 1,581,444 Warrants - -
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended Year ended $ $ Net loss, basic (6,881,812 ) (9,838,317 ) Effect of dilutive securities: Change in fair value of derivative liability (1,156,002 ) - Net loss, diluted (8,037,814 ) (9,838,317 ) Denominator 66,522,564 57,048,406 Effective of dilutive securities 503,980 - Diluted weighted average common shares outstanding 67,026,545 57,048,406 Basic net loss per share $ (0.10 ) $ (0.17 ) Diluted net loss per shares $ (0.12 ) $ (0.17 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year ended Year ended March 31, 2016 March 31, 2015 Options outstanding 5,875,360 4,920,000 Warrants outstanding 12,973,009 8,444,400 Total 18,848,369 13,364,400

RECAPITALIZATION (Tables)

RECAPITALIZATION (Tables)	12 Months Ended
	Mar. 31, 2016
Net Assets of Helius Acquired [Table Text Block]	Cash and cash equivalents $ 23,904 Receivables 1,644 Bridge loan receivable 150,000 Prepaid expenses 5,970 Accounts payable and accrued liabilities (18,628 ) $ 162,890

COMMON STOCK AND WARRANTS (Tabl

COMMON STOCK AND WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2016
Schedule of Warrants, Fair Values [Table Text Block]	Year ended Year ended Fair value of warrants, beginning of the period - - Issuance 1,536,134 - Change in fair value of warrants during the period (331,553) - Fair value of warrants, end of the period 1,204,581 -
Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions [Table Text Block]	March 31, 2016 Stock price $0.78 Exercise Price $1.62 Expected life 2.65 years Expected volatility 83.86% Risk – free interest rate 0.83% Dividend rate 0.00%
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	Number of warrants Weighted Average Exercise Price CAD US CAD US Balance, March 31, 2015 8,444,400 - $ 1.00 - Granted 4,528,609 $ - 1.62 Exercised (14,400 ) - $ 1.00 - Balance, March 31, 2016 8,430,000 4,528,609 $ 1.00 1.62
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of warrants outstanding Exercise Price Expiry Date 8,430,000 CAD $1.00 May 30, 2016 452,032 US $3.00 April 30, 2018 167,731 US $3.00 June 26, 2018 18,978 US $2.15 June 26, 2020 62,878 US $3.00 July 17, 2018 7,545 US $2.15 July 17, 2020 1,041,667 US $1.44 November 10, 2018 2,777,778 US $1.35 December 29, 2018

SHARE BASED PAYMENTS (Tables)

SHARE BASED PAYMENTS (Tables)	12 Months Ended
	Mar. 31, 2016
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Aggregate Exercise Price Intrinsic Value Number (CAD) (CAD) Balance outstanding at March 31, 2015 4,920,000 $ 1.14 $ 10,120,000 Exercised (94,640 ) $ 0.60 - Granted 1,850,000 $ 0.88 - Balance outstanding at March 31, 2016 6,675,360 $ 1.08 $ 1,580,883 Balance exercisable at March 31, 2016 4,336,864 $ 1.16 $ 1,064,963
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Options outstanding remaining Number of Number of contractual life Exercise Grant date fair options options Expiry date (years) Price (CAD) value (CAD) exercisable 3,520,000 June 18, 2019 3.22 $ 0.60 $ 0.26 2,346,669 155,360 June 20, 2019 3.22 $ 0.60 $ 0.26 155,360 100,000 July 14, 2017 1.29 $ 2.52 $ 1.05 100,000 450,000 December 8, 2019 3.69 $ 2.92 $ 1.65 450,000 100,000 December 8, 2019 3.69 $ 2.92 $ 1.31 66,667 400,000 December 8, 2019 3.69 $ 2.96 $ 1.29 300,000 100,000 March 16, 2020 4.96 $ 3.20 $ 1.42 66,667 50,000 August 15, 2015 4.38 $ 0.98 $ 0.39 16,667 750,000 October 21, 2020 4.56 $ 0.87 $ 0.36 187,500 550,000 October 28, 2020 4.58 $ 0.84 $ 0.44 550,000 400,000 October 28,2020 4.58 $ 0.84 $ 0.36 64,000 100,000 December 31, 2020 4.76 $ 1.24 $ 0.50 33,334 6,675,360 4,336,864
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 31, 2016 March 31, 2015 Stock price $0.82 CAD $1.85 CAD Exercise Price $0.87 CAD $2.20 CAD Expected life 3.75 years 3.9 years Expected volatility 67.85% 67.85% Risk – free interest rate 0.63% 1.32% Dividend rate 0.00% 0.00%
Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]	Year ended Year ended Fair value of non-employee options, beginning of the period 1,581,444 - Issuance - 767,879 Reallocation of vested non-employee options 690,885 74,190 Change in fair value of non-employee stock options during the period (1,751,150) 739,375 Fair value of non-employee options, end of the period 521,179 1,581,444
Schedule Of Non-Employee Stock Options Awards Valuation Assumptions [Table Text Block]	March 31, 2016 March 31, 2015 Stock price $0.97 CAD $3.20 CAD Exercise Price $1.52 CAD $1.90 CAD Expected life 3.23 years 4.24 years Expected volatility 84.62% 67.85% Risk – free interest rate 0.53% 1.31% Dividend rate 0.00% 0.00%
Share-Based Payments Classified in the Companys Statement of Operations and Comprehensive Loss [Table Text Block]	Year ended Year ended Consulting fees 239,064 1,167,281 Research and development 158,396 721,601 Wages and salaries 833,790 451,994 1,231,250 2,340,876

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2016
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	2016 2015 $ $ U.S 5,132,611 9,301,988 Non-U.S. 1,749,201 536,329 6,881,812 9,838,317
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2016 2015 $ $ Statutory tax rate 34.00% 34.00% Loss before income taxes (6,882,812 ) (9,838,317 ) Expected income tax recovery (2,340,000 ) (3,345,000 ) Increase (decrease) in income tax recovery resulting from: Derivative liability (708,000 ) 251,000 Share based payments 419,000 796,000 Other permanent difference 49,000 12,000 Share issue costs - (140,000 ) Effect of change in statutory rate (147,000 ) (41,000 ) Effect of foreign exchange - 89,000 Effect of over provision in prior year (2,164,000 ) - Foreign income taxed at foreign rate 100,000 14,000 Increase in valuation allowance 4,791,000 2,364,000 Income tax expense - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2016 2015 $ $ Deferred income tax assets (liabilities) Operating losses carried forward 4,915,000 2,074,000 Intangible costs - 285,000 Share issuance costs - 99,000 Stock compensation 1,725,000 - Other 609,000 Valuation allowance (7,249,000 ) (2,458,000 ) Net deferred income tax asset - -

DESCRIPTION OF BUSINESS AND B27

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Description Of Business And Basis Of Presentation 1	100.00%
Description Of Business And Basis Of Presentation 2	$ 6,881,812
Description Of Business And Basis Of Presentation 3	26,305,263
Description Of Business And Basis Of Presentation 4	$ 2,643,937

SIGNIFICANT ACCOUNTING POLICI28

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)mo
Significant Accounting Policies 1	3
Significant Accounting Policies 2 | $	$ (18,785)
Significant Accounting Policies 3 | $	$ 865,916
Significant Accounting Policies 4	50.00%
Significant Accounting Policies 5	12
Significant Accounting Policies 6	12

RECAPITALIZATION (Narrative) (D

RECAPITALIZATION (Narrative) (Details) - 12 months ended Mar. 31, 2016	USD ($)shares	CADCAD / sharesshares
Recapitalization 1	100.00%	100.00%
Recapitalization 2 | shares	35,300,083	35,300,083
Recapitalization 3	$ 150,000
Recapitalization 4	8.00%	8.00%
Recapitalization 5	$ 162,890
Recapitalization 6 | shares	15,240,000	15,240,000
Recapitalization 7 | CAD / shares		CAD 0.50
Recapitalization 8	$ 7,016,002
Recapitalization 9 | CAD		CAD 7,620,000
Recapitalization 10 | CAD		1
Recapitalization 11	$ 379,806
Recapitalization 12 | CAD		CAD 412,200
Recapitalization 13	824,400	824,400
Recapitalization 14 | CAD / shares		CAD 1

CONVERTIBLE DEBENTURE (Narrativ

CONVERTIBLE DEBENTURE (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)shares
Convertible Debenture 1	8.00%
Convertible Debenture 2	$ 1,000,100
Convertible Debenture 3	$ 2,000,000
Convertible Debenture 4	85.00%
Convertible Debenture 5	$ 8,500,000
Convertible Debenture 6 | shares	2,564,705
Convertible Debenture 7	$ 176,488
Convertible Debenture 8 | shares	2,564,705
Convertible Debenture 9	$ 11,131

PROMISSORY NOTE (Narrative) (De

PROMISSORY NOTE (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)shares
Promissory Note 1	$ 200,000
Promissory Note 2	6.00%
Promissory Note 3	10.00%
Promissory Note 4 | shares	30,000
Promissory Note 5 | shares	30,000
Promissory Note 6	30,000
Promissory Note 7	$ 29,045
Promissory Note 8	$ 1,644

CONVERTIBLE NOTE (Narrative) (D

CONVERTIBLE NOTE (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Convertible Note 1	$ 7,000,000
Convertible Note 2	2,000,000
Convertible Note 3	2,000,000
Convertible Note 4	5,000,000
Convertible Note 5	$ 2,000,000
Convertible Note 6	6.00%
Convertible Note 7	$ 2,000,000
Convertible Note 8 | $ / shares	$ 0.96
Convertible Note 9	$ 1.44
Convertible Note 10	2
Convertible Note 11	2,000,000
Convertible Note 12	425,208
Convertible Note 13	2,000,000
Convertible Note 14	$ 2,000,000
Convertible Note 15 | shares	2,083,333
Convertible Note 16 | $ / shares	$ 0.96
Convertible Note 17 | shares	1,041,667
Convertible Note 18	$ 1.44
Convertible Note 19	206,667
Convertible Note 20	268,334
Convertible Note 21	$ 5,000,000
Convertible Note 22	50.00%
Convertible Note 23	$ 5,000,000
Convertible Note 24 | shares	5,555,556
Convertible Note 25 | $ / shares	$ 0.90
Convertible Note 26 | shares	2,777,778
Convertible Note 27	$ 1.35
Convertible Note 28	5,000,000
Convertible Note 29	$ 796,945

COMMON STOCK AND WARRANTS (Narr

COMMON STOCK AND WARRANTS (Narrative) (Details) - 12 months ended Mar. 31, 2016	USD ($)yr$ / sharesshares	CADyrCAD / sharesshares
Common Stock And Warrants 1 | shares	35,300,083	35,300,083
Common Stock And Warrants 2 | CAD / shares		CAD 0.50
Common Stock And Warrants 3 | shares	15,240,000	15,240,000
Common Stock And Warrants 4	$ 7,016,002
Common Stock And Warrants 5 | yr	2	2
Common Stock And Warrants 6 | CAD		CAD 1
Common Stock And Warrants 7	$ 578,961
Common Stock And Warrants 8	$ 1,825,937
Common Stock And Warrants 9 | shares	849,273	849,273
Common Stock And Warrants 10	$ 2.15
Common Stock And Warrants 11 | $ / shares	$ 3
Common Stock And Warrants 12	$ 84,074
Common Stock And Warrants 13	27,396	27,396
Common Stock And Warrants 14 | $ / shares	$ 3
Common Stock And Warrants 15	$ 721,243
Common Stock And Warrants 16 | shares	335,463	335,463
Common Stock And Warrants 17	$ 2.15
Common Stock And Warrants 18 | $ / shares	$ 3
Common Stock And Warrants 19	$ 40,803
Common Stock And Warrants 20	18,978	18,978
Common Stock And Warrants 21 | $ / shares	$ 2.15
Common Stock And Warrants 22	$ 270,375
Common Stock And Warrants 23 | shares	125,756	125,756
Common Stock And Warrants 24	$ 2.15
Common Stock And Warrants 25 | $ / shares	$ 3
Common Stock And Warrants 26	$ 16,223
Common Stock And Warrants 27	7,545	7,545
Common Stock And Warrants 28 | $ / shares	$ 2.15
Common Stock And Warrants 29	$ 2,000,000
Common Stock And Warrants 30 | shares	2,083,333	2,083,333
Common Stock And Warrants 31 | $ / shares	$ 0.96
Common Stock And Warrants 32 | shares	1,041,667	1,041,667
Common Stock And Warrants 33	$ 1.44
Common Stock And Warrants 34	$ 5,000,000
Common Stock And Warrants 35 | shares	5,555,556	5,555,556
Common Stock And Warrants 36 | $ / shares	$ 0.90
Common Stock And Warrants 37 | shares	2,777,778	2,777,778
Common Stock And Warrants 38	$ 1.35

SHARE BASED PAYMENTS (Narrative

SHARE BASED PAYMENTS (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)yrshares
Share Based Payments 1	12,108,016
Share Based Payments 2	5,432,656
Share Based Payments 3 | $	$ 440,633
Share Based Payments 4 | yr	0.76
Share Based Payments 5	0.00%

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)mo
Income Taxes 1	$ 1,839,442
Income Taxes 2	$ 12,616,000
Income Taxes 3	50.00%
Income Taxes 4 | mo	12

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - 12 months ended Mar. 31, 2016	USD ($)dshares	EUR (€)dshares
Commitments And Contingencies 1 | shares	16,035,026	16,035,026
Commitments And Contingencies 2	4.00%	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	1,065,000
Commitments And Contingencies 5	1,389,000
Commitments And Contingencies 6	586,000
Commitments And Contingencies 7	$ 5,191,368
Commitments And Contingencies 8 | d	30	30
Commitments And Contingencies 9	$ 274,000
Commitments And Contingencies 10	120,448
Commitments And Contingencies 11	274,000
Commitments And Contingencies 12	300,000
Commitments And Contingencies 13	1,937,817
Commitments And Contingencies 14	2,928,289
Commitments And Contingencies 15	225,000
Commitments And Contingencies 16 | €		€ 57,000
Commitments And Contingencies 17	$ 2,000,000

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Related Party Transactions 1	$ 64,210
Related Party Transactions 2	47,100
Related Party Transactions 3	$ 3,450
Related Party Transactions 4	24,418
Related Party Transactions 5	$ 195,709
Related Party Transactions 6	$ 1,040,854

SOLE-SOURCE COST-SHARING AGRE38

SOLE-SOURCE COST-SHARING AGREEMENT (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)d
Sole-source Cost-sharing Agreement 1	$ 2,996,244
Sole-source Cost-sharing Agreement 2	62.00%
Sole-source Cost-sharing Agreement 3	$ 1,458,374
Sole-source Cost-sharing Agreement 4 | d	30

SUPPLEMENTAL CASH FLOW INFORM39

SUPPLEMENTAL CASH FLOW INFORMATION (Narrative) (Details)	12 Months Ended
	Mar. 31, 2016USD ($)shares
Supplemental Cash Flow Information 1	$ 532,522
Supplemental Cash Flow Information 2	2,000,000
Supplemental Cash Flow Information 3	5,000,000
Supplemental Cash Flow Information 4	$ 1,003,612
Supplemental Cash Flow Information 5 | shares	30,000
Supplemental Cash Flow Information 6	$ 29,045
Supplemental Cash Flow Information 7	$ 268,334
Supplemental Cash Flow Information 8 | shares	2,564,705
Supplemental Cash Flow Information 9	$ 1,000,100
Supplemental Cash Flow Information 10	176,488
Supplemental Cash Flow Information 11	$ 162,890

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - 12 months ended Mar. 31, 2016	USD ($)mo	CADmo
Subsequent Events 1		CAD 9,215,000
Subsequent Events 2		1
Subsequent Events 3		1.50
Subsequent Events 4		CAD 436,050
Subsequent Events 5	436,050	436,050
Subsequent Events 6		CAD 1
Subsequent Events 7 | mo	24	24
Subsequent Events 8 | $	$ 150,000
Subsequent Events 9 | $	$ 495,415
Subsequent Events 10	1,090,125	1,090,125
Subsequent Events 11		CAD 1
Subsequent Events 12		1,090,125
Subsequent Events 13		10,305,125
Subsequent Events 14		1.50
Subsequent Events 15		CAD 65,408
Subsequent Events 16	65,407	65,407
Subsequent Events 17		CAD 1
Subsequent Events 18 | mo	24	24
Subsequent Events 19		CAD 1,825,600

Fair Value, by Balance Sheet Gr

Fair Value, by Balance Sheet Grouping (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 521,179
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2	521,179
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	1,204,581
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4	1,204,581
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	378,000
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	378,000
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	$ 0

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 1	$ (6,881,812)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 2	(9,838,317)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 3	(1,156,002)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 4	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 5	(8,037,814)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 6	(9,838,317)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 7	66,522,564
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 8	57,048,406
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 9	503,980
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 10	0
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 11	67,026,545
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 12	$ 57,048,406
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 13	(0.10)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 14	(0.17)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 15	(0.12)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 16	(0.17)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 1	$ 5,875,360
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 2	4,920,000
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 3	12,973,009
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 4	8,444,400
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 5	18,848,369
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 6	$ 13,364,400

Net Assets of Helius Acquired (

Net Assets of Helius Acquired (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Recapitalization Net Assets Of Helius Acquired 1	$ 23,904
Recapitalization Net Assets Of Helius Acquired 2	1,644
Recapitalization Net Assets Of Helius Acquired 3	150,000
Recapitalization Net Assets Of Helius Acquired 4	5,970
Recapitalization Net Assets Of Helius Acquired 5	(18,628)
Recapitalization Net Assets Of Helius Acquired 6	$ 162,890

Schedule of Warrants, Fair Valu

Schedule of Warrants, Fair Values (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Common Stock And Warrants Schedule Of Warrants, Fair Values 1	$ 0
Common Stock And Warrants Schedule Of Warrants, Fair Values 2	0
Common Stock And Warrants Schedule Of Warrants, Fair Values 3	1,536,134
Common Stock And Warrants Schedule Of Warrants, Fair Values 4	0
Common Stock And Warrants Schedule Of Warrants, Fair Values 5	(331,553)
Common Stock And Warrants Schedule Of Warrants, Fair Values 6	0
Common Stock And Warrants Schedule Of Warrants, Fair Values 7	1,204,581
Common Stock And Warrants Schedule Of Warrants, Fair Values 8	$ 0

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions (Details)	12 Months Ended
	Mar. 31, 2016USD ($)yr
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 1	$ 0.78
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 2	$ 1.62
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 3 | yr	2.65
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 4	83.86%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 5	0.83%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 6	0.00%

Schedule of Stockholders' Equ47

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$ 8,444,400
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	1
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	4,528,609
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	1.62
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	$ (14,400)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	1
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	8,430,000
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	$ 4,528,609
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	1
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15	1.62

Schedule of Stockholders' Equ48

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - 12 months ended Mar. 31, 2016	USD ($)	CAD
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 1	$ 8,430,000
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 2 | CAD		CAD 1
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 3	452,032
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 4	3
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 5	167,731
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 6	3
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 7	18,978
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 8	2.15
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 9	62,878
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 10	3
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 11	7,545
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 12	2.15
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 13	1,041,667
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 14	1.44
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 15	2,777,778
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 16	$ 1.35

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 2	1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 3	$ 10,120,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 4	$ (94,640)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 5	0.60
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 6	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 7	$ 1,850,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 8	0.88
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 10	$ 6,675,360
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 11	1.08
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 12	$ 1,580,883
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 13	$ 4,336,864
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 14	1.16
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 1,064,963

Disclosure of Share-based Compe

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	$ 3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	3.22
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	0.26
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 2,346,669
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	$ 155,360
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	3.22
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	0.26
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	$ 155,360
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	1.29
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	2.52
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.05
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	3.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	1.65
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	3.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	1.31
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	$ 66,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	3.69
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	2.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	1.29
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 300,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	4.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	3.20
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	1.42
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	$ 66,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	$ 50,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	4.38
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	0.98
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	0.39
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	$ 16,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	$ 750,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	4.56
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43	0.87
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44	0.36
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45	$ 187,500
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46	$ 550,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47	4.58
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48	0.84
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49	0.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50	$ 550,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52	4.58
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53	0.84
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54	0.36
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55	$ 64,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57	4.76
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58	1.24
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59	0.50
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61	6,675,360
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62	$ 4,336,864

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Mar. 31, 2016USD ($)yr
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 0.82
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	1.85
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	0.87
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	$ 2.20
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 | yr	3.75
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 | yr	3.9
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	67.85%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	67.85%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	0.63%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	1.32%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	0.00%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.00%

Schedule of Non-Employee Share-

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 1	$ 1,581,444
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 2	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 3	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 4	767,879
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 5	690,885
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 6	74,190
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 7	(1,751,150)
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 8	739,375
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 9	521,179
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 10	$ 1,581,444

Schedule Of Non-Employee Stock

Schedule Of Non-Employee Stock Options Awards Valuation Assumptions (Details)	12 Months Ended
	Mar. 31, 2016USD ($)yr
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 1	$ 0.97
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 2	3.20
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 3	1.52
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 4	$ 1.90
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 5 | yr	3.23
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 6 | yr	4.24
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 7	84.62%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 8	67.85%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 9	0.53%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 10	1.31%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 11	0.00%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 12	0.00%

Share-Based Payments Classified

Share-Based Payments Classified in the Companys Statement of Operations and Comprehensive Loss (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 1	$ 239,064
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 2	1,167,281
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 3	158,396
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 4	721,601
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 5	833,790
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 6	451,994
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 7	1,231,250
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 8	$ 2,340,876

Schedule of Income before Incom

Schedule of Income before Income Tax, Domestic and Foreign (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 1	$ 5,132,611
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 2	9,301,988
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 3	1,749,201
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 4	536,329
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 5	6,881,812
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 6	$ 9,838,317

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 1	34.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 2	34.00%
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 3	$ (6,882,812)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 4	(9,838,317)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 5	(2,340,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 6	(3,345,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 7	(708,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 8	251,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 9	419,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 10	796,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 11	49,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 12	12,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 13	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 14	(140,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 15	(147,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 16	(41,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 17	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 18	89,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 19	(2,164,000)
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 20	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 21	100,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 22	14,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 23	4,791,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 24	2,364,000
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 25	0
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 26	$ 0

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1	$ 4,915,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2	2,074,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4	285,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6	99,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7	1,725,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 9	609,000
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 10	(7,249,000)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 11	(2,458,000)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 12	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 13	$ 0